Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma

Cargando...
Miniatura

Fecha

2012

Título de la revista

Publicado en

Lung Cancer, 1872-8332, Vol. 77, No. 2, 2012 p. 469-472

Publicado por

Elsevier

Enlace a contenidos multimedia

ISSN de la revista

Título del volumen

Resumen

Descripción

Abstract

The use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40 year-old female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebral metastasis, a EGFR mutation and no smoking history, who had begun first line treatment with erlotinib 150 mg once daily. After two and a half months of treatment a fourteen-week pregnancy was documented, and after informing on fetal risks secondary to erlotinib use and maternal risks secondary to treatment withholding, she decided to continue with treatment under clinical surveillance by both the oncology and obstetrics clinics. At thirty-three weeks gestation a live born 1600 g female was born by caesarean section without evidence of congenital malformations. Imaging assessment after eight months of treatment showed complete bone and central nervous system response and partial lung and mediastinal response. The patient is currently undergoing the 11th month of treatment and is asymptomatic, the baby is 4 months old and is in good health.

Palabras clave

Keywords

Lung cancer, Treatment, Metastasis, Non-small cell lung carcinoma, Lung adenocarcinoma, Erlotinib, Pregnancy, EGFR tyrosine kinase inhibitor

Temáticas

Neoplasias pulmonares
Neoplasias del sistema respiratorio
Embarazo

Citación

Colecciones